1988•Human ReproductionRequires access
Addition of Buserelin to human menopausal gonadotrophins in patients with failed stimulations for IVF or GIFT
Johan E. J. Smitz, Paul Devroey, Michael Alexis Villalobos Camus, I. Khan, C. Staessen, L. Van Waesberghe, Arjoko Wisanto, A.C. Van Steirteghem
Open publisher page 66 citations
Abstract
The combined therapy of a gonadotrophin-releasing hormone agonist (GnRHa) D-Ser(TBU)6-EA10-LHRH (Buserelin) and human menopausal gonadotrophins (HMG) for ovarian stimulation for in-vitro fertilization and gamete intra-Fallopian transfer was evaluated during 84 cycles. All women selected for this therapy had previously failed stimulations with clomiphene citrate/HMG. The GnRHa prevented spontaneous luteinizing hormone surges and premature luteinization in all patients. After addition of the agonist to HMG, the cancellation rate dropped from 17 to 7% and improved the results in 72.6% of the cycles. Twenty-six per cent of the started cycles resulted in a pregnancy. Eighteen healthy children were born at term.